The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Related Posts
Shares of LVMH drop 5% as full-year results throw doubt on broad luxury recovery
LVMH shares dropped as slightly better-than-expected full-year results from the world’s largest luxury company threw doubt over a broader sector…
As Trump Heads to Iowa to Trumpet Economy, Many Residents Feel Pain
Farmers are critical to Iowa’s economy. They have been battered by President Trump’s tariffs and are not yet experiencing the…
U.S. and Japan at Odds Over Terms of $550 Billion Investment
Claims that President Trump will direct Japanese investment highlight how trade frictions are mounting even with countries that have reached…